Open-Label Safety Study of Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE in Healthy Adults in India

This study has been completed.
Sponsor:
Collaborator:
Bill and Melinda Gates Foundation
Information provided by:
Infectious Disease Research Institute
ClinicalTrials.gov Identifier:
NCT00486382
First received: June 12, 2007
Last updated: March 16, 2009
Last verified: March 2009

June 12, 2007
March 16, 2009
April 2007
November 2008   (final data collection date for primary outcome measure)
Injection site reactions [ Time Frame: For 7 days following each injection. ] [ Designated as safety issue: Yes ]
  • injection site reactions [ Time Frame: For 7 days following each injection. ]
  • changes in laboratory values [ Time Frame: From study day 0 through study day 84. ]
  • changes in vital signs [ Time Frame: From study day 0 through study day 168. ]
  • adverse events [ Time Frame: From study day 0 through study day 168. ]
Complete list of historical versions of study NCT00486382 on ClinicalTrials.gov Archive Site
Not Provided
  • IgG antibody response to Leish-111f [ Time Frame: Serum samples will be collected at study day 0, study day 84 and study day 168. ]
  • T-cell response measured by cytokine production to Leish-111f [ Time Frame: T-cell response will be measured on study day 0, study day 84 and study day 168. ]
Not Provided
Not Provided
 
Open-Label Safety Study of Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE in Healthy Adults in India
A Phase 1, Open-Label, Dose Escalating Study to Evaluate the Safety, Tolerability, and Immunogenicity of the LEISH-111F + MPL-SE Vaccine (Recombinant Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE) in Healthy Adults In India

The purpose of this study is to determine if a vaccine (called Leish-111f + MPL-SE) is safe and whether it can or cannot produce a protective response against visceral leishmaniasis when injected to healthy subjects.

The purpose of this study is to determine the safety, tolerability, and immunogenicity of an investigational vaccine being developed for immunotherapy of visceral leishmaniasis (VL) and post kala-azar dermal leishmaniasis (PKDL). The vaccine, identified as Leish-111f + MPL-SE, consists of a recombinant three-antigen Leishmania polyprotein (Leish-111f) together with adjuvant MPL-SE.

The primary objective is to evaluate the safety and tolerability of the Leish-111f + MPL-SE vaccine given as three subcutaneous injections every 28 days at each of three dose levels of the Leish-111f protein (5 μg, 10 μg, or 20 μg) together with MPL-SE adjuvant (25 μg) in healthy adults.

The secondary objective is to assess the immunogenicity of the vaccine by evaluating T-cell and antibody response to the Leish-111f protein of the vaccine.

Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Visceral Leishmaniasis
  • Post-Kala-Azar Dermal Leishmaniasis
Biological: Leish-111f + MPL-SE Adjuvant
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
36
November 2008
November 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Males and females ≥ 18 years and < 55 years of age.
  • Must be in good general health as confirmed by a medical history and physical exam.
  • DAT titer must be <1:400 and rK39 serology negative (for inclusion in the DAT-negative group) or DAT titer ≥1:1600 (for inclusion in the DAT-positive group).
  • The following laboratory blood tests must have values within the normal ranges at screening (Appendix 4): sodium, potassium, urea, ALT, AST, total bilirubin, creatinine, alkaline phosphatase, glucose, hemoglobin, total WBC count and platelet count.
  • The following serology tests must be negative at screening: HIV 1/2, hepatitis B surface antigen (HBsAg), and hepatitis C virus (HCV) antibody. All subjects will receive HIV related counseling prior to testing. Subjects with positive HIV test results will receive counseling at the University and will be referred to the national AIDS control program for treatment if appropriate.
  • Subjects must give written informed consent, be willing and able to attend all required visits, have a permanent address, and be reachable by study site personnel.
  • Female subjects of childbearing potential must have a negative urine pregnancy test at screening, a negative urine pregnancy test within 24 hours before study injection, must not be breast-feeding, and are required to use adequate contraception through Day 84 of the study. These precautions are necessary due to unknown effects that Leish-111f + MPL-SE might have in a fetus or newborn infant.

Exclusion Criteria:

  • Previous exposure to Leishmania vaccines or experimental products containing MPL-SE.
  • Participation in another experimental protocol or receipt of any investigational products within 30 days prior to the first administration of study injection.
  • Known use of injected or oral corticosteroids within 6 weeks prior to the first administration of study injection.
  • History of autoimmune disease or other causes of immunosuppressive states.
  • History or evidence of any acute or chronic illness that, in the opinion of the Principal Investigator, may interfere with the evaluation of the safety or the immunogenicity of the vaccine. (Potential subjects presenting with concomitant illness will be referred for clinical care.)
  • History of use of any medication that, in the opinion of the Principal Investigator, may interfere with the evaluation of the safety or the immunogenicity of the vaccine.
  • History of significant psychiatric illness.
  • Known to be a current drug or alcohol abuser.
  • Subjects with a history of previous anaphylaxis, severe allergic reaction to vaccines or unknown allergens, or allergic reaction to eggs.
  • History of chronic headaches or migraine.
  • Subjects who are unlikely to cooperate with the requirements of the study protocol.
  • Subjects who are not permanent residents or who are planning to move to another town/city.
Both
18 Years to 54 Years
Yes
Contact information is only displayed when the study is recruiting subjects
India
 
NCT00486382
IDRI-LVVPX-104
Yes
Franco Piazza MD, Medical Director, Infectious Disease Research Institute
Infectious Disease Research Institute
Bill and Melinda Gates Foundation
Principal Investigator: Shyam Sundar, MD Banaras Hindu University
Study Director: Franco M Piazza, MD, MPh Infectious Disease Research Institute
Infectious Disease Research Institute
March 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP